Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

icetana - Change of Director's Interest Notice (ASX:ICE)

To view the Change of Director's Interest Notice, download the attached PDF.

Immutep to Present at Investor Conferences (ASX:IMM)

SYDNEY, AUSTRALIA – 20 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related imm...read more

Immutep - Leading Oncologists appointed to Clinical Advisory Board (ASX:IMM)

SYDNEY, AUSTRALIA – 18 May 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3-related imm...read more

INOVIQ Investor Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

Immutep - New & significant data from AIPAC phase 2b trial in MBC (ASX:IMM)

* Statistically significant increase in innate and adaptive immune response biomarkers (monocyte and CD8 T cell counts and serum CXCL10 levels) and absolute lymphocyte count (ALC) demonstrated in th...read more

Imdex - Macquarie Australia Conference 2022 Presentation (ASX:IMD)

To view the presentation, download the attached PDF.

icetana - Change in substantial holding (ASX:ICE)

To view the Notice of change of interests of substantial holder, download the attached PDF.

INOVIQ - Australian Patent Granted for SubB2M Technology (ASX:IIQ)

* AU Patent No 2017358401 granted covering the SubB2M technology * Provides IP protection in Australia for SubB2M-based diagnostics INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announc...read more

INOVIQ Key Manufacturing Agreement to Advance SubB2M tests (ASX:IIQ)

* INOVIQ has executed a Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company’s SubB2M-based tests * INOVIQ’s SubB2M technology detects...read more

INOVIQ Appendix 4C & Quarterly Activities Report - March 2022 (ASX:IIQ)

* Collaboration with the University of Queensland (UQ) expanded to develop a worldfirst exosome-based ovarian cancer screening test * ResearchDx, a US-based specialty contract diagnostics organisat...read more

Immutep - Quarterly Activities/Appendix 4C Cash Flow Report (ASX:IMM)

* New interim TACTI-002 data from 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients shows encouraging early overall survival rate of 73.7% at the six-month landmark * Constru...read more

icetana - Quarterly Activities Report (ASX:ICE)

icetana Limited (ASX: ICE) ("icetana" or "the Company" or "we"), a global software company providing artificial intelligence solutions to detect real-time anomalous eve...read more

icetana - Investor briefing (ASX:ICE)

icetana Limited (ASX: ICE) (“icetana” or “the Company” or “we”), a global software company providing artificial intelligence solutions to detect real-time anomalo...read more